Efficiency of rivaroxaban and enoxaparin in the prevention of venous thromboembolic events

Comparison of efficiency and safety of rivaroxaban and subcutaneous enoxaparin in the prevention of venous thromboembolic events after spinal instrumentation surgery

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120527009878N16

Enrollment

Registered

2023-07-22

Start date

2023-07-06

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal fusion. Osseous stenosis of neural canal

Interventions

Intervention 1: Intervention group: People who receive oral Rivaroxaban (Aboreihan Company) 10 mg twice a day after surgery for one week. Intervention 2: Control group: people who receive subcutaneous

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients who have undergone spine surgery and have no previous history of venous thromboembolism .

Exclusion criteria

Exclusion criteria: Patient dissatisfactionsm patients with coagulation disorders People with underlying diseases such as high blood pressure, diabetes and severe osteoporosis Patients with kidney failure

Design outcomes

Primary

Measure	Time frame
Inflammation. Timepoint: after surgery daily for 10 days. Method of measurement: Clinical evaluation.;Pain. Timepoint: after surgery daily for 10 days. Method of measurement: Clinical evaluation.;Differences in organ size. Timepoint: after surgery daily for 10 days. Method of measurement: Clinical evaluation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Farhad Mirzaei

Tabriz University of Medical Sciences

golzar.farhad@yahoo.com+98 41 3334 0830

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026